Navigation Links
NeurogesX Reports Third Quarter 2008 Results
Date:11/6/2008

Third Quarter 2008 Corporate Highlights: * Submitted NDA with FDA for NGX-4010 for management of pain associated

with PHN * Responded to EMEA's scheduled Day 120 questions regarding MAA under

review for NGX-4010 in peripheral neuropathic pain

SAN MATEO, Calif., Nov. 6 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today reported results for the quarter ended September 30, 2008.

During the third quarter, NeurogesX made significant progress on the regulatory front and continued pre-commercialization activities to support the potential marketing approvals and launch of NGX-4010. In October 2008, the new drug application (NDA) for NGX-4010 for the management of pain associated with postherpetic neuralgia (PHN) was submitted on schedule to the FDA. In September 2008, the Company submitted its response to the European Medicines Agency's (EMEA) scheduled Day 120 questions regarding the marketing authorization application (MAA) for NGX-4010. The MAA, filed under the centralized procedure, is currently under EMEA review for peripheral neuropathic pain.

Anthony DiTonno, President and CEO, commented, "NeurogesX is dedicated to advancing all activities necessary to support the potential marketing approvals of NGX-4010 in both Europe and the United States. We are thrilled with the progress we've made in the past two months with the submission of our NDA to the FDA for NGX-4010 for the management of pain associated with PHN, and the submission of our response to the EMEA's scheduled Day 120 questions regarding our MAA for peripheral neuropathic pain.
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
2. NeurogesX Appoints New Director to the Board
3. NeurogesX to Present at UBS 2007 Global Life Sciences Conference
4. NeurogesX Expands Senior Management Team
5. NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. NeurogesX to Present at Lazard Capital Markets Healthcare Conference
7. NeurogesX, Inc. Announces $25 Million Private Placement
8. NeurogesX Closes $25 Million Private Placement
9. NeurogesX to Present at the 10th Annual BIO CEO & Investor Conference
10. NeurogesX to Present at Roth 2008 OC Growth Stock Conference
11. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 Vermillion, Inc. ... on gynecologic disease, announced today that investors including ... Birchview Fund LLC and several Vermillion directors have ... shares of Vermillion,s common stock and warrants to ... a private placement.  Under the ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 The ... global leader of technical training across the life sciences ... Data Management (SCDM) to provide the organization's members ... programs —providing access to the more than 350 sessions ... members with 10% off when registering for a ...
(Date:12/22/2014)... 22, 2014  ( www.competitivehealth.com ) — Competitive Health ... bill review and advocacy service, has signed an agreement ... Savings discount health services marketplace. 63% of ... than they expected to pay. As part of an ... WellCard Savings is pleased to offer medical bill review ...
(Date:12/19/2014)... Lawrence, MA (PRWEB) December 19, 2014 ... flow MRLAFMQ test for the Detection of Aflatoxin M1 ... test to receive independent third party validation. The peer ... Science Unit of the Institute for Agricultural and Fisheries ... Francis Group. , Aflatoxin B1, the most toxic ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2
... woundcare division of,Insense Ltd., today announced it has received ... Oxyzyme product in the treatment of,difficult and chronic wounds. ... one of the world,s leading wound care specialists, in ... The announcement was made at,the 3rd Congress of the ...
... June 6 Inverness Medical,Innovations, Inc. (Amex: IMA ... for the consumer and professional markets, today,announced that it ... & Medical Technology Conference being held June 11-12, 2008,at ... Jon Russell, Vice President,Finance, will present on Thursday, June ...
... June 6 DURECT Corporation,(Nasdaq: DRRX ) announced today that ... New York, NY., -- Needham & Company,s ... June 12th at 11:30 a.m. EDT. -- Leerink Swann,s Pain ... 12:45 p.m. EDT. -- Jefferies, 2nd Annual Healthcare Conference on ...
Cached Biology Technology:Revolutionary Healing Technology for Treating Difficult and Chronic Wounds Approved by Health Canada 2
(Date:12/3/2014)... , Dec. 2, 2014   Marvin Test ... innovative test solutions for military, aerospace, and manufacturing ... of its successful TS-900 PXI semiconductor test ... features of high-end systems to customers at a ... compared to traditional ATE. "Our ...
(Date:11/21/2014)... November 18, 2014 According to ... by Systems (Video, RFID, Access Control, Intrusion Detection, Parking ... Banks, Government), Component Service Geography - Global Forecasts to ... is projected to be around $25 Billion in 2014 ... growing at a CAGR of 8.69%. Browse ...
(Date:11/21/2014)... 20, 2014 Strict laws against distracted driving ... the North American and European automotive sector towards gesture ... recognition systems that are intuitive and able to retrieve ... industry. New analysis from Frost & ... in Europe and ...
Breaking Biology News(10 mins):Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... study sheds additional light on how erectile dysfunction (ED) ... uncovering the link between the two disorders, and may ... study, "Lack of Central Nitric Oxide Triggers Erectile Dysfunction ... Mayhan, and Kaushik P. Patel, Departments of Cellular and ...
... therapy in mice to shut down a gene that plays ... , The technique, detailed in an upcoming issue of Vision ... material called interfering RNA, which helps disable the gene. ... mutated versions of it are passed from generation to generation ...
... made his way out of Africa some 60,000 years ... He was accompanied by the bacterium Helicobacter pylori, which ... the bacterium spread throughout the entire world. This is ... led by Mark Achtman from the Max Planck Institute ...
Cached Biology News:Erectile dysfunction in diabetes is due to selective defect in the brain 2Erectile dysfunction in diabetes is due to selective defect in the brain 3Gene therapy for blindness clears hurdle in mice 2Out of Africa -- Bacteria, as well 2
... X-Gal ,MOLECULAR BIOLOGY GRADE ,5-Bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside ... Br Cl N O 6 ... (HPLC) ,Solution: Clear (2% in DMF) ... pUC and M13 ,Elemental Analysis: Agrees ...
...
... MW: 34.2kDa Formulation: 10mM HEPES, pH ... dithiothreitiol with 50% glycerol Properites: For ... Certificate of Analysis for individual lots ... followed by gel filtration and Mono-S ...
Antibody Purification Specificity: Antibody Purification ...
Biology Products: